An innovative platform and smartphone app to deliver tailored interventions and facilitate completed referrals related to substance use.

一个创新的平台和智能手机应用程序,可提供量身定制的干预措施并促进完成与药物使用相关的转介。

基本信息

  • 批准号:
    10713171
  • 负责人:
  • 金额:
    $ 77.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-01 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Abstract The goal of this fast-track SBIR proposal is to increase patient adherence to SBIRT-related recommendations given to patients by a primary care provider (PCP). The success of SBIRT (Screening, Brief Intervention, and Referral to Treatment) in the primary care setting has been inconsistent in terms of patients following through on treatment referral recommendations, with averages as low as 10%. For a variety of reasons, many patients, irrespective of their specific disease, do not adhere well to clinical recommendations. One way to improve adherence has been to personalize the recommendations for each individual’s needs, especially using digital technology, such as apps. The aim of NIDA to develop a sophisticated smart phone based tool for improving patient follow up to SBIRT recommendations is therefore well justified. CHESS Health has already developed an automated digital tool (eIntervention) with key elements requested by this RFA. eIntervention is designed to encourage patient adherence to PCP recommendations following SBIRT. Using a variety of the RFA required functionalities, eIntervention is designed to facilitate and motivate each patient to enter treatment, once that patient has been identified by SBIRT as having a substance use disorder (SUD) or as being at risk of such. eIntervention is commercially available and was developed in response to customer requests. However, eIntervention does not contain all of the functionalities requested by NIDA in this RFA and we do not have data to validate efficacy. Such validation is important for supporting wide spread dissemination. We propose to enhance our existing eIntervention solution with new functionalities that address the requirements set forth in this RFA and carry out a randomized study of efficacy. In Phase I, our Specific Aim is to evaluate feasibility of our program for improving adherence to SBIRT recommendations to patients from PCPs. This Specific Aim will be accomplished in two Tasks: Task 1: Add functionality to our prototype that address most requirements outlined in the RFA. Task 2: Demonstrate acceptability, feasibility, and preliminary efficacy of the prototype eIntervention in improving patient linkage to and engagement in indicated follow-up specialty SUD care. If shown to be feasible, in Phase II, our Specific Aim is to evaluate a near commercial quality product that contains all of the features required by the RFA. The Specific Aim will be accomplished in two Tasks: Task 1: Modifications to the program (months 1-3). Task 2: The randomized clinical trial to test efficacy of SBIRT/eIntervention compared to SBIRT/TAU. Criteria for Success: We aim to double the current rate of follow-up specialty SUD care (e.g. go from ~17% to an achieved rate of ~35%), a highly impactful effect. All patients, including those identified as at risk, must show a reduction in substance use. Patients and PCPs must rank the program with an average of 3.5 on a five-point Likert scale for usability, satisfaction, and willingness to use with the program again.
摘要 这一快速SBIR提案的目标是提高患者对SBIRT相关建议的依从性 由初级保健提供者(PCP)提供给患者。SBIRT(筛查、短暂干预和 转诊治疗)在初级保健环境中的患者随访方面一直不一致, 平均低至10%。由于各种原因,许多患者, 无论其具体疾病如何,都不能很好地遵守临床建议。一种改进的方法 坚持一直是个性化的建议,为每个人的需要,特别是使用数字 技术,如APP。NIDA的目标是开发一个先进的智能手机为基础的工具, 因此,对SBIRT建议的患者随访是合理的。 CHESS Health已经开发了一种自动化数字工具(eIntervention),其中包含所需的关键要素 在这个RFA。eIntervention旨在鼓励患者遵循PCP建议, SBIRT。使用RFA所需的各种功能,电子干预旨在促进和激励 一旦患者被SBIRT确定为使用某种物质, 疾病(SUD)或处于这种风险中。eIntervention已上市,开发于 响应客户的要求。但是,eIntervention不包含 NIDA在该RFA中,我们没有数据来验证疗效。这种验证对于支持广泛的 传播传播。我们建议通过新功能增强现有的电子干预解决方案, 满足本RFA中规定的要求,并进行随机有效性研究。 在第一阶段,我们的具体目标是评估我们的计划的可行性,以提高遵守SBIRT 给患者的建议。这一具体目标将通过两项任务来实现: 任务1:为我们的原型添加功能,以满足RFA中概述的大多数需求。 任务2:证明原型电子干预在以下方面的可接受性、可行性和初步疗效: 改善患者与指定随访专科SUD护理的联系和参与。 如果证明是可行的,在第二阶段,我们的具体目标是评估一个接近商业质量的产品, 包含RFA所需的所有功能。具体目标将通过两项任务实现: 任务1:修改程序(1-3个月)。 任务2:随机临床试验,以测试SBIRT/eIntervention与SBIRT/TAU相比的疗效。 成功标准:我们的目标是将目前的随访专科SUD护理率提高一倍(例如,从约17%提高到 实现率约为35%),具有高度影响力的效果。所有患者,包括确定为有风险的患者,必须 显示药物使用减少。患者和PCP必须对该计划进行平均3.5分的评分, 五点Likert量表,用于可用性、满意度和再次使用该程序的意愿。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lisa Ellen Graves其他文献

Lisa Ellen Graves的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Data-driven Recommendation System Construction of an Online Medical Platform Based on the Fusion of Information
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    万元
  • 项目类别:
    外国青年学者研究基金项目

相似海外基金

SCH: Artificial Intelligence enabled multi-modal sensor platform for at-home health monitoring of patients
SCH:人工智能支持的多模式传感器平台,用于患者的家庭健康监测
  • 批准号:
    10816667
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
A miniaturized neural network enabled nanoplasmonic spectroscopy platform for label-free cancer detection in biofluids
微型神经网络支持纳米等离子体光谱平台,用于生物流体中的无标记癌症检测
  • 批准号:
    10658204
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
Advancing One Health Data Capture at the Point of Zoonotic Spillover in the Congo Basin Forest Perimeter
在刚果盆地森林周边人畜共患病蔓延时推进单一健康数据采集
  • 批准号:
    10741526
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
Reagentless Sensor Technologies For Continuous Monitoring of Heart Failure Biomarkers
用于连续监测心力衰竭生物标志物的无试剂传感器技术
  • 批准号:
    10636089
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
DEVELOPMENT OF A SALIVARY ASSAY FOR MEASURING PERIODONTAL DISEASE ACTIVITY
开发用于测量牙周疾病活动的唾液测定法
  • 批准号:
    10600906
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
A Sensor Patch for Continuous Monitoring of Sodium, Glucose, and Ketones Concurrently and in Real-Time
用于同时实时连续监测钠、葡萄糖和酮的传感器贴片
  • 批准号:
    10761499
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
Use of Digital Phenotyping to Understand Digital Media Influence on Adolescent Substance Use
使用数字表型来了解数字媒体对青少年药物使用的影响
  • 批准号:
    10661933
  • 财政年份:
    2023
  • 资助金额:
    $ 77.89万
  • 项目类别:
Development and testing of a digitally assisted risk reduction platform for youth at high risk for suicide
为自杀高危青少年开发和测试数字辅助风险降低平台
  • 批准号:
    10509791
  • 财政年份:
    2022
  • 资助金额:
    $ 77.89万
  • 项目类别:
In-home wearable system to detect early-stage decompensation in heart failure patients
家用可穿戴系统可检测心力衰竭患者的早期失代偿
  • 批准号:
    10676951
  • 财政年份:
    2022
  • 资助金额:
    $ 77.89万
  • 项目类别:
Digital implementation support strategies for caregiver home practice
护理人员家庭实践的数字化实施支持策略
  • 批准号:
    10667596
  • 财政年份:
    2022
  • 资助金额:
    $ 77.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了